Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| Incyte CorporationCOM | COM | $3,487,217,729 | 17.5% |
| Beone Medicines Ltd.SPONSORED ADS | SPONSORED ADS | $2,508,182,548 | 12.6% |
| Revolution Medicines, Inc..COM | COM | $2,143,111,899 | 10.7% |
| Madrigal Pharmaceuticals, Inc..COM | COM | $1,150,754,190 | 5.8% |
| Acadia Pharmaceuticals Inc..COM | COM | $1,085,696,471 | 5.4% |
| Kymera Therapeutics, Inc..COM | COM | $992,725,940 | 5.0% |
| Insmed IncorporatedCOM PAR $.01 | COM PAR $.01 | $937,841,355 | 4.7% |
| Celcuity Inc..COM | COM | $828,150,159 | 4.2% |
| Kodiak Sciences Inc..COM | COM | $776,051,487 | 3.9% |
| Rhythm Pharmaceuticals, Inc..COM | COM | $622,265,747 | 3.1% |
| Praxis Precision Medicines, Inc..COM | COM | $586,953,158 | 2.9% |
| Alkermes PLCSHS | SHS | $524,592,729 | 2.6% |
| Summit Therapeutics Inc..COM | COM | $477,697,090 | 2.4% |
| Grail, Inc..COM | COM | $275,033,478 | 1.4% |
| Abcellera Biologics Inc..COM | COM | $259,145,283 | 1.3% |
| Immunovant, Inc..COM | COM | $209,419,027 | 1.0% |
| Ideaya Biosciences, Inc..COM | COM | $186,723,818 | 0.9% |
| Kiniksa Pharmaceuticals International, PLCORD SHS CL A | ORD SHS CL A | $181,275,420 | 0.9% |
| Roivant Sciences Ltd.SHS | SHS | $166,928,649 | 0.8% |
| Arrowhead Pharmaceuticals, Inc..COM | COM | $162,431,742 | 0.8% |
| Ionis Pharmaceuticals, Inc..COM | COM | $162,364,274 | 0.8% |
| Edgewise Therapeutics, Inc..COM | COM | $150,400,843 | 0.8% |
| Replimune Group, Inc..COM | COM | $122,271,870 | 0.6% |
| Nurix Therapeutics, Inc..COM | COM | $113,016,569 | 0.6% |
| Stoke Therapeutics, Inc..COM | COM | $109,176,726 | 0.5% |
| Monte Rosa Therapeutics, Inc..COM | COM | $105,166,811 | 0.5% |
| Immatics N.V.SHS | SHS | $96,321,763 | 0.5% |
| Denali Therapeutics Inc..COM | COM | $96,047,122 | 0.5% |
| Crinetics Pharmaceuticals, Inc..COM | COM | $87,991,820 | 0.4% |
| Dianthus Therapeutics, Inc..COM | COM | $83,068,947 | 0.4% |
| Structure Therapeutics Inc..SPONSORED ADS | SPONSORED ADS | $76,883,831 | 0.4% |
| Celcuity Inc..Note 2.75% 8/1/2031 | Note 2.75% 8/1/2031 | $69,158,687 | 0.3% |
| Rapport Therapeutics, Inc..COM | COM | $64,467,240 | 0.3% |
| Alumis Inc..COM | COM | $56,631,750 | 0.3% |
| Prelude Therapeutics Inc..COM | COM | $53,959,982 | 0.3% |
| Relay Therapeutics, Inc..COM | COM | $52,889,110 | 0.3% |
| Mirum Pharmaceuticals, Inc..COM | COM | $52,210,293 | 0.3% |
| Bicycle Therapeutics PLCSPONSORED ADS | SPONSORED ADS | $46,153,914 | 0.2% |
| Enliven Therapeutics, Inc..COM | COM | $45,938,443 | 0.2% |
| Celldex Therapeutics, Inc..COM | COM | $44,004,955 | 0.2% |
| Viridian Therapeutics, Inc..COM | COM | $43,776,169 | 0.2% |
| Design Therapeutics, Inc..COM | COM | $38,756,882 | 0.2% |
| Entrada Therapeutics, Inc..COM | COM | $37,335,293 | 0.2% |
| Faeth Therapeutics, Inc..COM | COM | $32,160,275 | 0.2% |
| Aktis Oncology, Inc..COM | COM | $32,112,393 | 0.2% |
| Neurogene Inc..COM | COM | $31,188,682 | 0.2% |
| Jade Biosciences, Inc..COM | COM | $27,340,066 | 0.1% |
| Taysha Gene Therapies, Inc..COM SHS | COM SHS | $27,272,388 | 0.1% |
| Arcus Biosciences, Inc..COM | COM | $26,045,677 | 0.1% |
| Disc Medicine, Inc..COM | COM | $25,573,913 | 0.1% |
Incyte CorporationCOM$3,487,217,729
- Class
- COM
- Share
- 17.5%
Beone Medicines Ltd.SPONSORED ADS$2,508,182,548
- Class
- SPONSORED ADS
- Share
- 12.6%
Revolution Medicines, Inc..COM$2,143,111,899
- Class
- COM
- Share
- 10.7%
Madrigal Pharmaceuticals, Inc..COM$1,150,754,190
- Class
- COM
- Share
- 5.8%
Acadia Pharmaceuticals Inc..COM$1,085,696,471
- Class
- COM
- Share
- 5.4%
Kymera Therapeutics, Inc..COM$992,725,940
- Class
- COM
- Share
- 5.0%
Insmed IncorporatedCOM PAR $.01$937,841,355
- Class
- COM PAR $.01
- Share
- 4.7%
Celcuity Inc..COM$828,150,159
- Class
- COM
- Share
- 4.2%
Kodiak Sciences Inc..COM$776,051,487
- Class
- COM
- Share
- 3.9%
Rhythm Pharmaceuticals, Inc..COM$622,265,747
- Class
- COM
- Share
- 3.1%
Praxis Precision Medicines, Inc..COM$586,953,158
- Class
- COM
- Share
- 2.9%
Alkermes PLCSHS$524,592,729
- Class
- SHS
- Share
- 2.6%
Summit Therapeutics Inc..COM$477,697,090
- Class
- COM
- Share
- 2.4%
Grail, Inc..COM$275,033,478
- Class
- COM
- Share
- 1.4%
Abcellera Biologics Inc..COM$259,145,283
- Class
- COM
- Share
- 1.3%
Immunovant, Inc..COM$209,419,027
- Class
- COM
- Share
- 1.0%
Ideaya Biosciences, Inc..COM$186,723,818
- Class
- COM
- Share
- 0.9%
Kiniksa Pharmaceuticals International, PLCORD SHS CL A$181,275,420
- Class
- ORD SHS CL A
- Share
- 0.9%
Roivant Sciences Ltd.SHS$166,928,649
- Class
- SHS
- Share
- 0.8%
Arrowhead Pharmaceuticals, Inc..COM$162,431,742
- Class
- COM
- Share
- 0.8%
Ionis Pharmaceuticals, Inc..COM$162,364,274
- Class
- COM
- Share
- 0.8%
Edgewise Therapeutics, Inc..COM$150,400,843
- Class
- COM
- Share
- 0.8%
Replimune Group, Inc..COM$122,271,870
- Class
- COM
- Share
- 0.6%
Nurix Therapeutics, Inc..COM$113,016,569
- Class
- COM
- Share
- 0.6%
Stoke Therapeutics, Inc..COM$109,176,726
- Class
- COM
- Share
- 0.5%
Monte Rosa Therapeutics, Inc..COM$105,166,811
- Class
- COM
- Share
- 0.5%
Immatics N.V.SHS$96,321,763
- Class
- SHS
- Share
- 0.5%
Denali Therapeutics Inc..COM$96,047,122
- Class
- COM
- Share
- 0.5%
Crinetics Pharmaceuticals, Inc..COM$87,991,820
- Class
- COM
- Share
- 0.4%
Dianthus Therapeutics, Inc..COM$83,068,947
- Class
- COM
- Share
- 0.4%
Structure Therapeutics Inc..SPONSORED ADS$76,883,831
- Class
- SPONSORED ADS
- Share
- 0.4%
Celcuity Inc..Note 2.75% 8/1/2031$69,158,687
- Class
- Note 2.75% 8/1/2031
- Share
- 0.3%
Rapport Therapeutics, Inc..COM$64,467,240
- Class
- COM
- Share
- 0.3%
Alumis Inc..COM$56,631,750
- Class
- COM
- Share
- 0.3%
Prelude Therapeutics Inc..COM$53,959,982
- Class
- COM
- Share
- 0.3%
Relay Therapeutics, Inc..COM$52,889,110
- Class
- COM
- Share
- 0.3%
Mirum Pharmaceuticals, Inc..COM$52,210,293
- Class
- COM
- Share
- 0.3%
Bicycle Therapeutics PLCSPONSORED ADS$46,153,914
- Class
- SPONSORED ADS
- Share
- 0.2%
Enliven Therapeutics, Inc..COM$45,938,443
- Class
- COM
- Share
- 0.2%
Celldex Therapeutics, Inc..COM$44,004,955
- Class
- COM
- Share
- 0.2%
Viridian Therapeutics, Inc..COM$43,776,169
- Class
- COM
- Share
- 0.2%
Design Therapeutics, Inc..COM$38,756,882
- Class
- COM
- Share
- 0.2%
Entrada Therapeutics, Inc..COM$37,335,293
- Class
- COM
- Share
- 0.2%
Faeth Therapeutics, Inc..COM$32,160,275
- Class
- COM
- Share
- 0.2%
Aktis Oncology, Inc..COM$32,112,393
- Class
- COM
- Share
- 0.2%
Neurogene Inc..COM$31,188,682
- Class
- COM
- Share
- 0.2%
Jade Biosciences, Inc..COM$27,340,066
- Class
- COM
- Share
- 0.1%
Taysha Gene Therapies, Inc..COM SHS$27,272,388
- Class
- COM SHS
- Share
- 0.1%
Arcus Biosciences, Inc..COM$26,045,677
- Class
- COM
- Share
- 0.1%
Disc Medicine, Inc..COM$25,573,913
- Class
- COM
- Share
- 0.1%
The share class is shown on a wider screen.
The 50 largest of 84 positions by value, with holdings of the same security combined. The 84 largest are in this firm's machine-readable record. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 1263508
- File number
- 028-10519
- Options
- 0 call, 0 put
- In the 25 largest
- 91.3%
- Prior quarter
- $17,415,689,929 at 31 March 2026
- Positions opened
- 8
- Positions closed
- 8
Common questions
What are Baker Bros. Advisors’ 13F holdings worth?
$19,955,238,553 across 84 positions for the quarter ended 30 June 2026.
What is Baker Bros. Advisors’ largest 13F holding?
Incyte Corporation (COM) was the largest position at $3,487,217,729, or 17.5% of reported 13F value, as of 30 June 2026.
How concentrated is Baker Bros. Advisors’ 13F portfolio?
The ten largest positions accounted for 72.8% of reported value and the twenty-five largest for 91.3%, across 84 positions as of 30 June 2026.
Does Form 13F show everything Baker Bros. Advisors manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Baker Bros. Advisors file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.